U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14O6
Molecular Weight 182.1718
Optical Activity ( - )
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANNITOL

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=FBPFZTCFMRRESA-KVTDHHQDSA-N
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1

HIDE SMILES / InChI

Molecular Formula C6H14O6
Molecular Weight 182.1718
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Sorbitol is a polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. Used as a non-stimulant laxative via an oral suspension or enema. Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. Sorbitol plays a vital step in the 'polyol pathway'. The sudden injection of extra sorbitol can ruin the equilibrium of enzymes that regulate the conversion of glucose to fructose in a process associated with the onset of diabetes and its complications. Further, the polyol pathway is involved with a complex network of metabolic activities; disruption leads to a cascade of problems (citations here, here and here) such as mitochondrial failure, cell apoptosis (cell death), and DNA fragmentation. In general, sorbitol induces cell hyperosmotic stress resulting in phosphorylation (uptake of phosphorus into cell) — an important on/off switch regulating enzymes and signaling networks.

CNS Activity

Curator's Comment: Mannitol does not cross the blood-brain barrier so an elevated plasma osmolality due to an infusion of hypertonic mannitol is effective in removing fluid from the brain.

Originator

Sources: https://books.google.ru/books?id=_F1YSezlIzwC&pg=PA268&lpg=PA268&dq=mannitol retrieved from Carbohydrates, p.268Alternative Sweeteners, Third Edition, Revised and Expanded. Ed. Lyn O'Brien-Nabors. CRC Press, 2001 . - pp. 572
Curator's Comment: Manufactured - Atlas Powder Company, Wilmington, Delaware, 1937

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Osmitrol

Approved Use

Osmitrol Injection (Mannitol Injection, USP) is indicated for: The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances.

Launch Date

1964
Primary
Osmitrol

Approved Use

Osmitrol Injection (Mannitol Injection, USP) is indicated for: The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances.

Launch Date

1964
Primary
Osmitrol

Approved Use

Osmitrol Injection (Mannitol Injection, USP) is indicated for: The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances.

Launch Date

1964
Diagnostic
ARIDOL

Approved Use

Mannitol, the active ingredient in ARIDOL, is indicated for the assessment of bronchial hyperresponsiveness in patients 6 years of age or older who do not have clinically apparent asthma.

Launch Date

2010
Palliative
Bronchitol

Approved Use

Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.

Launch Date

2012
Primary
SORBITOL 3.3% IN PLASTIC CONTAINER

Approved Use

Renagel Capsules are indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD). The safety and efficacy of Renagel Capsules in ESRD patients who are not on hemodialysis have not been studied. In hemodialysis patients, Renagel decreases the incidence of hypercalcemic episodes relative to patients on calcium acetate treatment.

Launch Date

1978
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Stereocontrolled total synthesis of (+)-streptazolin by a palladium-catalyzed reductive diyne cyclization.
2004-08-20
Cytochrome c release occurs via Ca2+-dependent and Ca2+-independent mechanisms that are regulated by Bax.
2001-06-01
Effects of P-glycoprotein on cell volume regulation in mouse proximal tubule.
2001-05
Alveolar epithelial barrier functions in ventilated perfused rabbit lungs.
2001-05
Theoretical description of transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis.
2001-05
Design and validation of an annular shear cell for pharmaceutical powder testing.
2001-05
The production of reactive oxygen species by irradiated camphorquinone-related photosensitizers and their effect on cytotoxicity.
2001-05
Cysteine cross-linking defines part of the dimer and B/C domain interface of the Escherichia coli mannitol permease.
2001-04-20
The effect of Celsior solution on 12-hour cardiac preservation in comparison with University of Wisconsin solution.
2001-04
Effect of high glucose concentration on the synthesis of monocyte chemoattractant protein-1 in human peritoneal mesothelial cells: involvement of protein kinase C.
2001-04
Head injury.
2001-04
Transcytosis of retinol-binding protein across renal proximal tubule cells after megalin (gp 330)-mediated endocytosis.
2001-04
Methemoglobin oxidation of N-acetylbenzidine to form a sulfinamide.
2001-04
Modulation of colonic barrier function by the composition of the commensal flora in the rat.
2001-04
A physiological analysis of hyponatremia: implications for patients on peritoneal dialysis.
2001-03-31
Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans.
2001-03-27
Celsior is superior to UW for graft preservation from non-heart-beating donors in a canine liver transplantation model.
2001-03-27
Pancreas preservation with Celsior solution in a pig autotransplantation model: comparative study with University of Wisconsin solution.
2001-03-27
Randomized clinical study comparing UW and Celsior solution in liver preservation for transplantation: preliminary results.
2001-03-27
Isolation and phenotypic characterization of Pseudomonas aeruginosa pseudorevertants containing suppressors of the catabolite repression control-defective crc-10 allele.
2001-03-15
Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells.
2001-03-14
Singlet oxygen generation from phosphatidylcholine hydroperoxide in the presence of copper.
2001-03-02
Melatonin counteracts potentiation by lysophosphatidylcholine of serotonin-induced vasoconstriction in human umbilical artery: relation to calcium influx.
2001-03
Identification of a mannitol transporter, AgMaT1, in celery phloem.
2001-03
Monosaccharide uptake in common carp (Cyprinus carpio) EPC cells is mediated by a facilitative glucose carrier.
2001-03
Modeling of supercritical extraction of mannitol from plane tree leaf.
2001-03
Mannitol-induced toxicity in a diabetic patient receiving losartan.
2001-03
Osmotherapy: a call to arms.
2001-03
Intraplatelet calcium levels in patients with acute renal failure before and after the administration of loop diuretics.
2001-03
Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function.
2001-03
The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency.
2001-02-23
The combined hydrolysis and hydrogenation of inulin catalyzed by bifunctional Ru/C.
2001-02-15
Permeability of the proximal and distal rat colon crypt and surface epithelium to hydrophilic molecules.
2001-02
Preferential induction of a 9-lipoxygenase by salt in salt-tolerant cells of Citrus sinensis L. Osbeck.
2001-02
[Intraoperative complications of 697 consecutive operative hysteroscopies].
2001-02
Intestinal permeability in adult patients with growth hormone deficiency.
2001-02
Improving water stress tolerance of the biocontrol yeast Candida sake grown in molasses-based media by physiological manipulation.
2001-02
The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus.
2001-02
Pathophysiologic features and prevention of human and experimental acute tubular necrosis.
2001-02
Mannitol-induced acute manic state.
2001-02
The use of hypertonic saline in the treatment of traumatic brain injury.
2001-02
Combined injection of rAAV with mannitol enhances gene expression in the rat brain.
2001-02
Hyperosmotic stress induces a rapid and transient increase in inositol 1,4,5-trisphosphate independent of abscisic acid in Arabidopsis cell culture.
2001-02
Survey of the use of intracranial pressure monitoring in children in the United Kingdom.
2001-01
Membrane-bound sugar alcohol dehydrogenase in acetic acid bacteria catalyzes L-ribulose formation and NAD-dependent ribitol dehydrogenase is independent of the oxidative fermentation.
2001-01
Development of a lyophilized formulation for (R,R)-formoterol (L)-tartrate.
2001-01
Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis.
2001-01
Intestinal permeability tests in coeliac disease.
2001
Mannitol for acute stroke.
2001
Hypertonicity stimulates Cl(-) transport in the intestine of fresh water acclimated eel, Anguilla anguilla.
2001
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 3% sorbitol solution is used as irrigation solution during urinary tract surgery https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5f7be402-f25a-428e-b81f-6a4a00de894c&type=pdf&name=5f7be402-f25a-428e-b81f-6a4a00de894c
OSMITROL Injection (Mannitol Injection, USP) should be administered only by intravenous infusion. The total dosage, concentration, and rate of administration should be governed by the nature and severity of the condition being treated, fluid requirement, and urinary output. The usual adult dosage ranges from 20 to 100 g in a 24 hour period, but in most instances an adequate response will be achieved at a dosage of approximately 50 to 100 g in a 24 hour period. The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50 mL/hour. This outline of administration and dosage is only a general guide to therapy.
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: The effects of allopurinol (10(-6)-10(-5) M), deferoxamine (10(-4) M) and mannitol (10(-4)-5 x 10(-3) M) were tested on the transient contraction induced by nicotine. In conclusion, mannitol (5 x 10(-3) M) significantly reduced contractile response to nicotine on EFS only in high concentration. Whereas in small concentrations mannitol (10(-4) M) statistically did not cause any results. https://www.ncbi.nlm.nih.gov/pubmed/20085573
Four different iodinated X-ray contrast agents--three of them with two different iodine concentrations--and mannitol (negative control; concentration of 150 mg mannitol per ml blood) were pipetted into blood samples so that there was a concentration of 0, 7.5 or 15 mg of iodine per ml blood in the samples.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:49:26 GMT 2025
Edited
by admin
on Mon Mar 31 17:49:26 GMT 2025
Record UNII
3OWL53L36A
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
D-MANNITOL
WHO-IP  
Preferred Name English
MANNITOL
EP   FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
MANNITOL [EP MONOGRAPH]
Common Name English
MANNITOL [HSDB]
Common Name English
MANNITOL [USP-RS]
Common Name English
ISOMALT IMPURITY, MANNITOL- [USP IMPURITY]
Common Name English
INS NO.421
Code English
D-MANNITOL [WHO-IP]
Common Name English
OSMITROL
Brand Name English
E-421
Code English
MANNITE
Common Name English
Mannitol [WHO-DD]
Common Name English
D-(-)-MANNITOL
Common Name English
MANNITOL [ORANGE BOOK]
Common Name English
MANNITOL [FCC]
Common Name English
MANNITOL [EP IMPURITY]
Common Name English
RESECTISOL
Brand Name English
D-MANNITOL [JAN]
Common Name English
MANNITOL [VANDF]
Common Name English
ISOMALT IMPURITY B [EP IMPURITY]
Common Name English
SORBITOL-MANNITOL COMPONENT MANNITOL
Common Name English
CORDYCEPIC ACID
Common Name English
NSC-407017
Code English
MANNITOL [USP MONOGRAPH]
Common Name English
BRONCHITOL
Brand Name English
MANNITOL, D-
Common Name English
MANNITOLUM [WHO-IP LATIN]
Common Name English
MANNITOL [MART.]
Common Name English
LACTITOL MONOHYDRATE IMPURITY C [EP IMPURITY]
Common Name English
INS-421
Code English
MANNITOL [MI]
Common Name English
MANNITOL [II]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BRONCHITOL (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
EU-Orphan Drug EU/3/05/325
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-ATC R05CB16
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-ATC B05BC01
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 16
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-VATC QB05CX04
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
NCI_THESAURUS C49187
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
NDF-RT N0000175359
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
LOINC 55941-9
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
DSLD 1364 (Number of products:8)
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
NDF-RT N0000010288
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-ATC A06AD16
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
NDF-RT N0000175810
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-ATC B05CX04
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
FDA ORPHAN DRUG 198704
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-VATC QB05BC01
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
FDA ORPHAN DRUG 277009
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-VATC QA06AD16
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-421
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
JECFA EVALUATION INS-421
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
WHO-VATC QR05CB16
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
Code System Code Type Description
CAS
87-78-5
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
NON-SPECIFIC STEREOCHEMISTRY
DAILYMED
3OWL53L36A
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
CHEBI
29864
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-711-8
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
EVMPD
SUB03087MIG
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
MESH
D008353
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
DRUG CENTRAL
935
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
CAS
69-65-8
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
RS_ITEM_NUM
1375105
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
RXCUI
6628
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL689
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID1023235
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
NCI_THESAURUS
C625
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
DRUG BANK
DB00742
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
FDA UNII
3OWL53L36A
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
WIKIPEDIA
MANNITOL
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
PUBCHEM
6251
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
CHEBI
16899
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
NSC
407017
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
MANNITOL
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Freely soluble in water; very slightly soluble in ethanol (~750 g/l) TS: practically insoluble in ether R. Category: Diuretic. Storage: Mannitol should be kept in a well-closed container. Additional information: Mannitol has a sweet taste. Definition: Mannitol contains not less than 98.0% and not more than 102.0% of C6H14O6, calculated with reference to the driedsubstance.
EVMPD
SUB20970
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
SMS_ID
100000091382
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY
MERCK INDEX
m7080
Created by admin on Mon Mar 31 17:49:26 GMT 2025 , Edited by admin on Mon Mar 31 17:49:26 GMT 2025
PRIMARY Merck Index
Related Record Type Details
SUB_CONCEPT->SUBSTANCE
SUB_CONCEPT->SUBSTANCE
SUB_CONCEPT->SUBSTANCE
SUB_CONCEPT->SUBSTANCE
SUB_CONCEPT->SUBSTANCE
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY